Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: A systematic review and meta-analysis

Genetics and Molecular Research

Volumn 13, Issue 1, 2014, Pages 1109-1120

  Liu, X ^a   Zhang, W ^b   Geng, D ^c   He, J ^b   Zhao, Y ^b   Yu, L ^a  

^a FUDAN UNIVERSITY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Bladder cancer; FGFR3; Grade; Prognosis; Staging

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; FGFR3 PROTEIN, HUMAN;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; EARLY CANCER; FGFR3 GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; NONHUMAN; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; AGED; BLADDER TUMOR; FEMALE; GENETICS; MALE; META ANALYSIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL;

AGED; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84897550953     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.February.20.12     Document Type: Article

References (41)

1. Al-Ahmadie HA, Iyer G, Janakiraman M, Lin O, et al. (2011). Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J. Pathol. 224: 270-279.
2. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, et al. (2003). FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 63: 8108-8112.
3. Bakkar AA, Allory Y, Iwatsubo Y, de Medina SG, et al. (2010). Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. Mol. Carcinog. 49: 25-31.
4. Bernard-Pierrot I, Brams A, Dunois-Larde C, Caillault A, et al. (2006). Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27: 740-747.
5. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, et al. (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158: 1955-1959.
6. Bodoor K, Ghabkari A, Jaradat Z, Alkhateeb A, et al. (2010). FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 34: 724-732.
7. Borenstein M, Hedges LV, Higgin JP and Rothstein HR (2009). Introduction to Meta-Analysis. John Wiley & Sons, New York, 33-39.
8. Bryan RT, Zeegers MP, James ND, Wallace DM, et al. (2010). Biomarkers in bladder cancer. BJU Int. 105: 608-613.
9. Burger M, van der Aa MN, van Oers JM, Brinkmann A, et al. (2008). Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol. 54: 835-843.
10. Cheng L, Zhang S, MacLennan GT, Williamson SR, et al. (2011). Bladder cancer: translating molecular genetic insights into clinical practice. Hum. Pathol. 42: 455-481.
11. Di Martino E, L'Hote CG, Kennedy W, Tomlinson DC, et al. (2009). Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type-and mutation-specific manner. Oncogene 28: 4306-4316.
12. Dodurga Y, Tataroglu C, Kesen Z and Satiroglu-Tufan NL (2011). Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet. Mol. Res. 10: 86-95.
13. Eltze E, Wild PJ, Wulfing C, Zwarthoff EC, et al. (2009). Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur. Urol. 56: 837-845.
14. Hernández S, Lopez-Knowles E, Lloreta J, Kogevinas M, et al. (2005). FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin. Cancer Res. 11: 5444-5450.
15. Hernández S, Lopez-Knowles E, Lloreta J, Kogevinas M, et al. (2006). Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 24: 3664-3671.
16. Iyer G and Milowsky MI (2013). Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol. Oncol. 31: 303-311.
17. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, et al. (2005). FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24: 5218-5225.
18. Junker K, van Oers JM, Zwarthoff EC, Kania I, et al. (2008). Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia 10: 1-7.
19. Kaufman DS, Shipley WU and Feldman AS (2009). Bladder cancer. Lancet 374: 239-249.
20. Kimura T, Suzuki H, Ohashi T, Asano K, et al. (2001). The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92: 2555-2561.
21. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, et al. (2010). FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5: e13821.
22. Lindgren D, Liedberg F, Andersson A, Chebil G, et al. (2006). Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 25: 2685-2696.
23. Miyake M, Sugano K, Sugino H, Imai K, et al. (2010). Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci. 101: 250-258.
24. Mukhtar S and Perry MJ (2011). Future prospects for bladder cancer biomarkers. BJU Int. 108: 1541-1543.
25. Ouerhani S, Rouissi K, Kourda N, Marrakchi R, et al. (2009). Combined analysis of smoking, TP53, and FGFR3 mutations in Tunisian patients with invasive and superficial high-grade bladder tumors. Cancer Invest. 27: 998-1007.
26. Parmar MK, Torri V and Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17: 2815-2834.
27. Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, et al. (2003). Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 98: 737-744.
28. Serizawa RR, Ralfkiaer U, Steven K, Lam GW, et al. (2011). Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int. J. Cancer 129: 78-87.
29. Sjödahl G, Lauss M, Gudjonsson S, Liedberg F, et al. (2011). A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 6: e18583.
30. Stroup DF, Berlin JA, Morton SC, Olkin I, et al. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
31. Tomlinson DC, Baldo O, Harnden P and Knowles MA (2007). FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213: 91-98.
32. van der Aa MN, van Leenders GJ, Steyerberg EW, van Rhijn BW, et al. (2005). A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum. Pathol. 36: 981-986.
33. van Oers JM, Wild PJ, Burger M, Denzinger S, et al. (2007). FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur. Urol. 52: 760-768.
34. van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, et al. (2009). FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur. Urol. 55: 650-657.
35. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, et al. (2003). Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol. 21: 1912-1921.
36. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, et al. (2004). FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 64: 1911-1914.
37. van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, et al. (2010). Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur. Urol. 58: 433-441.
38. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, et al. (2012). The FGFR3 mutation is related to favorable pT1 bladder cancer. J. Urol. 187: 310-314.
39. Wallerand H, Bakkar AA, de Medina SG, Pairon JC, et al. (2005). Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis 26: 177-184.
40. Youssef RF, Mitra AP, Bartsch G Jr, Jones PA, et al. (2009). Molecular targets and targeted therapies in bladder cancer management. World J. Urol. 27: 9-20.
41. Zieger K, Marcussen N, Borre M, Orntoft TF, et al. (2009). Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. Int. J. Cancer 125: 2095-2103.